Investment6 Mar 2025, 11:02 pm
Biocon Biologics and Civica Collaborate to Expand Insulin Aspart Access in the US
AI Summary
Biocon Biologics Ltd (BBL) and Civica, Inc. have announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Biocon Biologics will supply Insulin Aspart drug substance to Civica, who will produce Insulin Aspart drug product at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the US. This collaboration is in addition to Biocon Biologics’ own Insulin Aspart Drug Product for the US which is currently under U.S. Food and Drug Administration (FDA) review.
Key Highlights
- Biocon Biologics to supply Insulin Aspart drug substance to Civica, Inc.
- Civica to produce Insulin Aspart drug product at its Petersburg, Virginia facility.
- Civica to commercialize the medicine for patients in the US.
- Collaboration is in addition to Biocon Biologics’ own Insulin Aspart Drug Product for the US under FDA review.
- Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars.